Domestic "Peier" will be launched soon

　　Pharmaceutical Network November 22, a few days ago, Watson Biohuman Resources Director, President's Office Director Sun Qing said in public, its heavy products 13 price pneumonia vaccine will soon be listed By then, Watson Bio will become the world's best-selling vaccine varieties of enterprises it is understood that streptococcus pneumoniae is the main pathogen causing acute respiratory infection in infants and the elderly, is the highest incidence of bacterial respiratory infections, infants and young children due to the immune system development is not mature and the elderly immune function degradation, is a high-risk group of pneumococcal infection, it can lead to multi-system diseases in the clinic, including pneumonia, meningitis Sepsis, etc., according to WHO estimates that 1.6 million people die each year from pneumococcal infections, of which 460,000 are infants and young children; 13-price pneumonia vaccine (Perer 13® vaccine) developed by Pfizer to prevent pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F-induced invasive diseases (including bacteremia pneumonia, meningitis, septicaemia and bacteriosis) was approved by the FDA in 2010 After the introduction of the 13-price pneumonia vaccine in the United States, the incidence of pneumococcal pneumonia decreased from 80 per 100,000 in 1998 to three per 100,000 in 2012, and the protection was not good In 2014, the FDA approved the expansion of the 13-price pneumonia vaccine to people aged 50 and over, and in November 2016, Pei was approved by the former State Administration of Food and Drug Administration to officially enter the Chinese market to help infants from 6 weeks to 15 months of age prevent the disease from 13 serotypes of pneumococcal diseases in the global market, the 13-price ye-peer vaccine has been the best-selling vaccine variety, many times among the world's best-selling drug TOP10, in Pfizer's case, Peier is more "profit cow", in Pfizer's revenue structure, the contribution of the 13-price pneumonia vaccine gradually increased, in 2018, the vaccine global sales reached $5.802 billion as the fastest-growing in the research of 13-price pneumonia vaccine in China, Watson bio-declared 13-price pneumonia vaccine applicable to the population and immune programs are: 6 weeks to 15 months old infants and young children; Previously, Watson Bio has repeatedly disclosed its 13-price pneumonia vaccine development progress In January 2018, the vaccine completed clinical trials, in February of the same year, Watson Bio announced that the 13-price pneumonia vaccine listing application was accepted by the National Drug Administration, there are reports that Watson bio13 valor pneumonia combined vaccine and Pfizer 13 price vaccine in the United States have selected Pfizer 7 valente pneumonia vaccine non-poor control clinical data, test results show that Watson 13 valence pneumonia vaccine clinical trials in vaccine characteristics, clinical design, evaluation criteria and test results Many of the standards and data results are even better than Pfizer's 13-price pneumonia vaccine, in March 2018, Watson's 13-price pneumonia vaccine was placed on the priority review process application list, in September 2018, the technical review process was completed, the approval process also entered the final stage, in September 2019, Watson Bio completed and passed the registration of the species production site inspection and certification inspection industry insiders said that Watson 13 price pneumonia combined vaccine is expected to be approved for sale this year, with Pfizer to carry out positive competition, based on the current policy market environment and the overall competitive landscape, Watson 13 price pneumonia combined vaccine listed, is expected to quickly monopolize the domestic market and become the largest vaccine varieties in the country, combined with Pfizer Variety - Peier previously won the bid price of 698 yuan / branch, some analysts believe that if the domestic pricing of 500 yuan / branch, in China's annual newborn 12 million penetration rate of 20%, then the market demand volume of 9.6 million units, the market size of 4.8 billion yuan at the same time, in addition to Watson Biology, Minhai Bio, Beijing Kexing Zhongwei, Lanzhou Bio-Kantai Bio have received 13 price pneumonia combined vaccine clinical approval in addition, Watson Bio has an update on the 9-price HPV vaccine (which is currently undergoing Phase I clinical trials, watson bio-2-price HPV vaccine is currently in the final stage of case collection and analysis in Phase III clinical trials, and the industrialproduction workshop has been completed) On November 7, Watson Bio announced that Shanghai Zerun, a controlling subsidiary of the company, had signed an agreement with the Bill and Melinda Gates Foundation ("Gates Foundation") to obtain a $2.5 million project fund from the Gates Foundation to accelerate the clinical research and industrialization of the 9-price HPV vaccine Watson Bio said that the signing of this agreement shows that Shanghai Zerun and its 9-price HPV vaccine project has been recognized by international organizations, after the 9-price HPV vaccine has been pre-certified by the WHO (WHO pre-certification is in accordance with international quality, safety and performance standards for the evaluation of and diagnostic products system), will enter the international organization bulk , paving the way for Shanghai Zerun to enter the international market.